https://events.diabetes.org/p/s/long-term-treatment-with-the-ultra-long-acting-glp-1-receptor-agonist-met-097-pf-08653944-in-adults-with-obesity-or-overweight-the-vesper-1-open-label-extension-5619
The VESPER-2b Trial of Berobenatide in Adults with Overweight/Obesity and Type 2 Diabetes -...
Disclosures - I. LINGVAY: Consultant; Current; Aadvarak Therapeutics, Abbvie, Alveus Therapeutics, Amgen, Antag Therapeutics, Arrowhead Pharmaceuticals, Astra...